In the interim report that Acarix submitted today, 12 November 2020, there is a minor error under the
heading “Capitalization” (page 4 in the interim report) where the last sentence is to end with 2022 and
The correct sentence reads: " The Board assesses that cash balance as of the balance sheet date will
cover the Company’s working capital requirements until the second quarter of 2022."
A corrected version of the interim report is available at www.acarix.se
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.